Tempest Therapeutics, Inc. business relationships
Companies named in Tempest Therapeutics, Inc.’s 10-K filed 2026-03-30, and public companies whose annual reports name Tempest Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- <1 / 100 Top 11% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Tempest Therapeutics, Inc.’s annual report 3
“The Phase 1b/2 trial was a randomized, multicenter, global study in collaboration with Roche that was evaluating amezalpat in combination with atezolizumab (TECENTRIQ®) and bevacizumab (Avastin®) in previously untreated patients with advanced HCC, compared to atezolizumab and bevacizumab alone, whic...” SEC filing
“Data not provided by Roche” SEC filing
“On November 19, 2025, Erigen entered into an Amended and Restated License and Collaboration Agreement (the "Restated Factor License Agreement") with Factor Bioscience Limited.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.